Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) major shareholder Ltd Nirland sold 1,368,991 shares of Conduit Pharmaceuticals stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $0.10, for a total value of $136,899.10. Following the transaction, the insider now owns 7,031,009 shares in the company, valued at approximately $703,100.90. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Ltd Nirland also recently made the following trade(s):
- On Monday, October 7th, Ltd Nirland sold 939,009 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.10, for a total value of $93,900.90.
- On Wednesday, October 2nd, Ltd Nirland sold 333,177 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.10, for a total value of $33,317.70.
- On Monday, September 30th, Ltd Nirland sold 1,016,823 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.12, for a total value of $122,018.76.
Conduit Pharmaceuticals Trading Up 6.5 %
Shares of CDT stock opened at $0.11 on Wednesday. The stock has a 50 day moving average of $0.15 and a 200-day moving average of $1.51. Conduit Pharmaceuticals Inc. has a 12 month low of $0.10 and a 12 month high of $7.83.
Wall Street Analyst Weigh In
Separately, Berenberg Bank upgraded shares of Conduit Pharmaceuticals to a “strong-buy” rating in a research report on Friday, July 26th.
Get Our Latest Analysis on CDT
Conduit Pharmaceuticals Company Profile
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Featured Stories
- Five stocks we like better than Conduit Pharmaceuticals
- Insider Buying Explained: What Investors Need to Know
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- Golden Cross Stocks: Pattern, Examples and Charts
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- The Risks of Owning Bonds
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.